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ABSTRACT 
Purpose 
Thoracic aortic aneurysm/aortic dissection (TAAD) is a disorder with highly variable 
age of onset and phenotype. We sought to determine the prevalence of pathogenic 
variants in TAAD-associated genes in a mixed cohort of sporadic and familial TAAD 
patients and identify relevant genotype-phenotype relationships. 
Methods  
We used a targeted PCR and next generation sequencing-based panel for genetic 
analysis of 15 TAAD associated genes in 1025 unrelated TAAD cases. 
Results 
 We identified 49 pathogenic or likely pathogenic (P/LP) variants in 47 cases (4.9% of 
those successfully sequenced). Almost half of the variants were in non-syndromic 
cases with no known family history of aortic disease. Twenty-five variants were within 
FBN1 and two patients were found to harbour two P/LP variants. Presence of a 
related syndrome, younger age at presentation, family history of aortic disease and 
involvement of the ascending aorta increased the risk of carrying a P/LP variant. 
Conclusions 
Given the poor prognosis of TAAD that is undiagnosed prior to acute rupture or 
dissection, genetic analysis of both familial and sporadic cases of TAAD will lead to 
new diagnoses, more informed management and possibly reduced mortality through 
earlier, preclinical diagnosis in genetically determined cases and their family 
members. 
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INTRODUCTION 
Thoracic aortic aneurysm/aortic dissection (TAAD) manifests a devastating clinical 
course if undiagnosed and untreated 1. Recent studies of post-mortem computerised 
tomographic autopsy indicate that 7% of out-of-hospital sudden deaths are due to 
Type A aortic dissection 2.	
The major mortality and morbidity associated with TAAD lies with acute dissection or 
rupture, both of which are difficult to predict 1,3. Early perioperative mortality of a 
ruptured aneurysm remains high (28-46%) despite recent advances in surgical 
technology compared with the safety of elective treatment of unruptured thoracic 
aneurysms where surgical results have improved significantly (6-7% mortality) 4. 
Aneurysm size (5-5.5cm) is currently the major determinant of the timing of surgery5. 
In syndromic aortic disease (Marfan (MFS), Loeys-Dietz (LDS), Ehlers-Danlos 
Syndrome (EDS)), earlier surgical intervention is recommended as dissection can 
occur at diameters less than 5.0cm 6 although these associated syndromes may be 
difficult to diagnose 7,8. Whilst genetic testing is recommended in familial and 
syndromic TAAD, it is not widely available in sporadic TAAD (STAAD) and is 
generally restricted to those with a strong suspicion of a genetic aetiology5,9.	
The study of large pedigrees with multiply affected members has led to the 
identification of causal genes in both syndromic and non-syndromic TAAD 6,10. 
Causative mutations have been identified in non-syndromic FTAAD pedigrees within 
the smooth muscle contractile (SMC) genes ACTA2, MYH11, PRKG1 and MYLK in 
non-syndromic patients 11–13. Syndromic TAAD is associated with numerous 
connective tissue disorders and their corresponding genes; Marfan syndrome 
(FBN1), Loeys-Dietz syndrome (TGFBR1, TGFBR2, SMAD3 & TGFB2), Ehlers-
Danlos syndrome (COL1A1, COL1A2, COL3A1, COL5A1 and COL5A2), Arterial 
tortuosity syndrome (SLC2A10) and Shprintzen-Goldberg syndrome (SKI) 10,14. 	
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Many of the genes in syndromic TAAD are associated with dissections occurring in 
patients with an aortic size below the 5.5cm threshold recommended for reparative 
surgery 6. The identification of causal variants in probands can lead to additional 
diagnoses by family screening in family members who have yet to develop clinical 
manifestations of the disorder 9. In addition, endovascular repair is contraindicated in 
cases diagnosed with a connective tissue syndrome, when open surgery is 
recommended 15. Genetic testing can therefore identify causal variants leading to a 
definitive preclinical diagnosis that can better determine the optimal timing and 
technique of prophylactic surgery.	
Next generation sequencing (NGS) is increasingly used for mutation testing and 
clinical diagnosis 16. Using a cost-effective PCR and NGS-based targeted 
sequencing approach 17,18, we sought to identify the prevalence of causative genetic 
variants in known TAAD genes and to elucidate genotype-phenotype relationship in a 
mixed cohort of 1,025 cases of familial and sporadic TAAD from the UK and USA.	
 
 
METHODS 
Patient Cohorts 
Surgical intervention in 927 consecutive unrelated cases was undertaken over a 10 
year period at the Aortic Institute at Yale-New Haven (Yale University, New Haven, 
USA): 785 surgical samples from these cases were used for DNA analysis within this 
study (Yale cohort) and 240 unrelated cases, treated and followed up at three UK 
centres from 2000-2013 (St Mary’s hospital, London; Royal Brompton & Harefield 
hospitals, London; Liverpool Heart & Chest Hospital, Liverpool) (UK cohort) were 
recruited to the study. Twenty-five cases within the Yale cohort were also present in 
a previous whole-exome sequencing study 9. The Yale cohort was approved by the 
Human Investigation Committee of Yale University (IRB protocol 12617) and the UK 
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cohort was approved by the West London Research Ethics Committee (REC 
reference 11/LO/0883). Both cohorts complied with the Declaration of Helsinki and 
written informed consent was obtained from all participants. MFS and LDS diagnoses 
in the UK cohort were identified by clinical case note review in which diagnoses were 
made by consultant clinical geneticists following a standard referral pathway. MFS 
diagnoses in the Yale cohort were made according to the Revised Ghent Nosology19. 
There were no LDS cases in the Yale cohort.	
 
DNA Extraction 
For the UK cohort, saliva samples were collected using the Oragene DNA kit 
(Genotek, Ontario, Canada) and QIAamp DNA Blood Midi kit (Qiagen, Venlo, 
Netherlands) was used to extract DNA from whole-blood samples. For the Yale 
cohort, DNA from fresh frozen aortic specimens collected at surgery were extracted 
using the DNeasy Blood & Tissue kit (Qiagen, Venlo, Netherlands). All DNA samples 
were subsequently normalized to 25-50ng/ul. 
 
Targeted Exon Sequencing 
Targeted exon sequencing was carried out on two Fluidigm assays named 
Aortopathy panel 1 (TAAD-X), which included 363 primer-pairs for FBN1, TGFBR1, 
TGFBR2, MYH11, ACTA2, SMAD3 and MYLK and Aortopathy panel 2 (TAAD-Z) 
containing 493 primer pairs for SKI, TGFB2, SLC2A10, COL1A1, COL1A2, COL3A1, 
COL5A1 and COL5A2 (Table S1 & S2). Multiplex PCR was performed using the 
Access Array System (Fluidigm, South San Francisco, CA) and the MiSeq 
sequencing platform (Illumina, San Diego, CA) as previously described 17,18. 	
 
Read Mapping, Variant Calling & Annotation 
FastQC was used to assess the sequencing read quality. Primer sequences were 
trimmed from FASTQ files using cutadapt (v 1.9.1) 20 prior to read mapping to 
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GRCh37/hg19 human reference sequence using BWA-MEM V0.7.12 21. Realignment 
of reads around indels and base quality score recalibration was performed using 
GATK v3.4 22. The GATK UnifiedGenotyper was used for calling variants 23. Variants 
were annotated using Ensembl Variant Effect Predictor v84 24.	
 
Variant and Sample Filtering 
Synonymous variants and intronic variants (excluding splice sites) were omitted from 
downstream analysis unless annotated as pathogenic or disease-causing in ClinVar 
25 or HGMD 26 databases. Variants with a minor allele frequency greater than 0.1% in 
either ExAC release 0.3.1 27 or dbSNP146 28 datasets were excluded. We found a 
high frequency of false positives in variants within SKI exon 1 and those with an 
allele balance below 0.3. These variants were therefore excluded from the datasets. 
Samples with less than 80% of target bases covered by more than 49 reads were not 
considered for downstream analysis. 	
 
Pathogenicity Assignment  
Variants passing filters were assigned to one of three categories: either ‘pathogenic’, 
‘likely pathogenic’, ‘variant of uncertain significance (VUS)’ or ‘likely benign’ based on 
the presence of one or more pieces of evidence (Table S3 & S4).  Variants were 
assigned to the ‘pathogenic’ or ‘likely pathogenic’ category if they met any of the 
following criteria: if the variant is already reported as disease causing in HGMD or 
ClinVar unless sufficient evidence could not be found for categorising it as 
‘pathogenic/likely pathogenic’ (P/LP) (Table S5); if the variant results in the same 
amino acid substitution as a variant already reported as disease causing in HGMD  
or ClinVar; premature termination of translation; a substitution of a glycine residue 
within a GlyXY repeat in collagen triple helical domains; an insertion of amino acids 
disrupting the GlyXY repeat sequence; alteration of a key residue in a protein feature 
(e.g. active site, disulphide bond) in keeping with previously ascribed molecular 
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mechanisms for a given gene (see Table S6). Variants predicted to be damaging by 
PolyPhen and SIFT and with CADD scores above 10 were assigned to the VUS 
category, as were variants resulting in a substitution at an amino acid position at 
which a different substitution is assigned disease-causing status in ClinVar or HGMD 
25,26,29–31. Absence of PolyPhen or SIFT predictions for missense variants resulted in 
classification as VUS. Remaining variants were assigned ‘likely benign’ status. All 
variants assigned P/LP status were validated by Sanger sequencing. 	
 
Statistical Analysis 
Significant differences in categorical variables between individuals in different 
genotype or phenotype groups were estimated by Fisher’s exact test. The unpaired 
Wilcoxon rank-sum test was used to assess non-parametric phenotypic continuous 
measurements. 
 
 
RESULTS 
Patient Demographics and Clinical Characteristics 
Of the total of 785 cases recruited to the Yale cohort and 240 to the UK cohort, 
sequence depth reached the assay threshold of 50 reads in at least 80% of target 
bases in 93% of the Yale cohort and 98% of the UK cohort. A total of 732 patients in 
the Yale cohort and 235 patients in the UK cohort were therefore taken forward for 
further analyses: their demographic and clinical characteristics are given in Table 1. 
 
Variants Identified by NGS 
We identified 17 pathogenic variants, 32 likely pathogenic variants and 68 VUS within 
the whole cohort. Two patients, Y_91_1 and Y_17_1, each carried two P/LP variants, 
giving a total of 49 P/LP variants in 47 patients, constituting 4.9% of the 967 samples 
sequenced to our target threshold (Tables 2 and S7). The majority of the identified 
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P/LP variants were in the FBN1 gene (n = 25) (Figure 1, Table S7). A total of 68 VUS 
were found within 67 patients (Table S8).	
We also tested our pipeline with a more lenient allele frequency threshold of 1%, 
which yielded three more P/LP variants. However, each of these additional variants 
were reclassified to VUS upon inspection of the literature (Table S5), so a maximum 
allele frequency of 0.1% was used for all variant filtering.	
 
Genotype-phenotype correlation with P/LP variants 
A lower age at diagnosis was found to significantly increase the likelihood of 
identifying a P/LP variant. The median age at diagnosis was 46.0 years for patients 
carrying a P/LP variant compared to 55.5 years for those carrying a VUS (p=3.5e-3), 
and 61.0 for those in the likely benign and no variant group (p=3.4e-8) (Figure 2a).  
Patients who were diagnosed under 50 years of age were far more likely to carry a 
P/LP variant with 11.6% of those diagnosed before 50 carrying a P/LP variant 
compared to 3.0% in the over 50 category (p=1.3e-7) (Figure 2b). Removing Marfan 
cases from these datasets increases the median age at diagnosis for patients 
harbouring a P/LP variant to 51.5 (Figure 2c) and decreases the percentage of 
patients under 50 harbouring a P/LP variant to 7.8% (Figure 2d). The median age of 
TAAD diagnosis in clinically suspected MFS cases was 33.5 years in our cohort. 
TAAD patients with a family history were four times more likely to carry a P/LP 
variant than those without a family history (p=1.05e-4; Figure S1a). Gender did not 
significantly influence the likelihood of harbouring a P/LP variant within our cohorts 
(p=0.29; Figure S1b). A median maximum aortic size of 5.25cm was found in patients 
harboring P/LP variants compared to 5.1cm in those not harboring a P/LP variant (p 
= 0.45). Although aortic size is the main determinant for surgery, no association was 
found in our cohorts between maximum aortic size and variant categories 
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(unpublished data). Similarly, splitting the data by pathology type and location yielded 
nothing significant (unpublished data). 
To estimate the influence of clinical characteristics in determining the likelihood of 
obtaining a genetic diagnosis, we calculated the relative risk of detecting a P/LP 
variant by clinical phenotype (Table 3). Likelihood of genetic diagnosis was 
associated with presence of a related syndrome, a younger age at diagnosis, family 
history of aortic disease and ascending aortic aneurysm compared to other locations. 
All but 7 of patients harbouring a P/LP variant possessed at least one of these 
phenotypes. Other clinical features yielded small, non-significant risk.  
A median age at diagnosis of 39 and 29 was observed in patients who carried a P/LP 
variant within FBN1 (n=25) and TGFBR2 (n=3) respectively (Figure S2). Of the 24 
cases of clinically diagnosed MFS, 10 cases were identified as harbouring a P/LP 
variant in FBN1; the remaining case (Y_35_28) in whom a presumptive genetic 
diagnosis was made had a likely pathogenic variant in MYH11 (Table 2). Although no 
pathogenic FBN1 variants were found in this patient by our panel assay, subsequent 
clinical exome analysis identified a probable copy number variant in FBN1 in this 
patient (unpublished data), suggesting two possible genetic causes for this patient’s 
TAAD. 
DISCUSSION 
To date, the majority of genetic abnormalities in TAAD have been identified in 
syndromic or familial cases 6. The aim of our study was to determine the prevalence 
of likely disease-causing variants in a mixed, clinically relevant cohort of patients with 
sporadic and familial TAAD. We sequenced 967 of 1025 unselected TAAD patients 
from the UK and USA above our target coverage threshold and identified a total of 49 
P/LP variants in 47 patients that are the likely cause of their disease. To our 
knowledge, this is the largest genetic analysis of familial and sporadic cases of TAAD 
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to date and defines a lower limit of 4.9% for the prevalence of TAAD in our cohorts 
with a pathogenic abnormality amongst most of the currently known TAAD genes. 
This frequency is similar to that of deleterious mutations (3.9%) reported previously in 
a series of 102 TAAD patients analysed by exome sequencing 9.	
The majority (87.8%) of identified P/LP variants were found within known syndromic 
genes. Mutations in FBN1 accounted for more than half of all identified P/LP variants, 
with the majority affecting functionally significant domains of the gene. P/LP variants 
in FBN1 were discovered in 2.6% of the sequenced cohort and 5.8% of patients who 
had a probable or proven family history of TAAD.  This is somewhat higher than was 
reported in a previous study of FTAAD, in which 2.7% of familial cases carried a 
pathogenic FBN1 variant 32. 	
FBN1 is clearly an important contributor to Mendelian cases of TAAD and MFS. A 
recent genome-wide association study showed that common variants in FBN1 are 
associated with STAAD, suggesting a common pathogenesis of thoracic aortic 
disease in MFS and STAAD 33. We found that only 40% of those with a P/LP variant 
in FBN1 had a known or suspected clinical diagnosis of MFS. Similarly, only 48.9% 
of those with a P/LP variant in any gene had a known or probable family history of 
TAAD. Although these results may be partly due to an incomplete clinical record (UK 
records did not definitively record the absence of a family history), they are also 
consistent with observations over the last 20 years that FBN1 mutations are a cause 
of TAAD in patients who do not have clinical MFS 32,34. In keeping with this, a recent 
study of probands with FBN1 mutations found that, only 56-79% met formal clinical 
criteria for MFS by Ghent systemic scores 35.	
Patients Y_91_1 and Y_17_1 were each found to harbour two P/LP variants (in 
SLC2A10 and MYH11, and FBN1 and COL1A1 respectively). No common 
phenotypic features (young age-of-onset, family history) were seen in these two 
patients, although a much larger maximum aortic size was found in both patients 
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(7cm and 6.5cm respectively) compared to the median maximum aortic size 
identified in patients harbouring a P/LP variant (5.25cm). 
The age at diagnosis within our patients that have a P/LP variant (46.0 years) is 
much lower than has been observed previously in FTAAD (56.8 years) and STAAD 
(64.3 years) patients 36. This is likely due to the fact that 11 of the 47 patients 
harbouring a P/LP variant had clinically suspected MFS, 10 of whom had a P/LP 
variants in FBN1. The diagnosis of TAAD in MFS has been reported to have a lower 
age at diagnosis (24.8 years) than non-syndromic TAAD 36; our cohort had a similarly 
lower age at diagnosis (33.5 years). If the patients in our cohort with suspected MFS 
are removed, the median age of TAAD diagnosis in our cohort rises from 46.0 to 51.5 
years. Overall, the percentage of patients with a P/LP variant was 3-4x higher within 
the under 50 age group than in those over the age of 50.	
Although aortic size is the main determinant for surgery, we found no association 
between maximum aortic size and variant categories. This may in part be explained 
by early evaluation and surgical intervention in cases with syndromic presentations or 
family history of TAAD.	
Comparing all 47 patients with a P/LP variant with the rest of the cohort, we were 
able to identify statistically significant risks of carrying a P/LP variant associated with 
developing the disorder: a syndromic component (RR 11.94; 95% CI 7.06-20.20), a 
younger age at presentation (RR 3.83; 95% CI 2.20-6.67), a probable or known 
family history of aortic disease (RR 3.80; 95% CI 1.88-7.66) and an aneurysm or 
dissection occurring partially or wholly within the ascending aorta (RR 1.84; 95% CI 
1.04-3.27). The first three factors are clearly suggestive of Mendelian disease and 
may be suitable criteria for prioritizing TAAD patients for genetic testing if genetic 
testing is not applied to all cases. The fourth factor, disease location in the ascending 
aorta, is reflective of the known stronger genetic aetiology of TAAD in the ascending 
aorta compared to the descending aorta 9.	
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Previous studies have suggested that genetic testing should be undertaken in 
patients who present at a young age without any additional risk factors 37, although it 
is unclear to what extent this is implemented in routine clinical practice. Non-
syndromic TAAD can have a similarly severe clinical course to those with syndromic 
TAAD 38, highlighting the importance of identifying genetically predisposed, non-
syndromic TAAD patients prior to the development of symptoms. Seven (14.9%) 
patients harbouring a P/LP variant did not possess any of the above phenotypes 
(syndromic features, young age-of-onset, family history, involvement of the 
ascending aorta) associated with greater risk of a genetic aetiology. Therefore, whilst 
these risk factors increase the likelihood of identifying P/LP variants in known TAAD 
genes, restricting genetic testing solely to cases with these risk factors would miss a 
significant, albeit low percentage (14.9%) of cases in whom a genetic diagnosis could 
be made. 	
Our study has a number of limitations that include possibly having underestimated 
the number of truly pathogenic variants. We employed intentionally stringent criteria 
for defining P/LP variants, but this may have led to a number of truly pathogenic 
variants being classified as VUS’s. The difficulty in unequivocally designating variants 
as either P/LP or benign highlights the need for concerted efforts to systematically 
classify mutations in these disease genes, for example with prospective functional 
assays39. As more information becomes available we anticipate that many of the 
VUS identified in this study, particularly those with strong supporting in silico data, 
(Tables S8 and S9) may be unambiguously reclassified as causative variants. A 
further limitation to our study is that our sequencing assay is limited to the coding 
sequences and intron/exon boundaries of 15 TAAD genes that represent most of the 
common causes of TAAD - our study would not detect variants in as yet 
undiscovered genes or in non-coding sequence. In time, with greater understanding 
of genotype-phenotype correlation, whole genome sequencing could ultimately 
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detect a higher frequency of pathogenic variants than detected herein. Indeed, we 
were unable to identify a P/LP variant in 44 of 62 individuals with three or more of the 
risk factors we identified as increasing the likelihood of harbouring a P/LP variant, 
and only eight of these individuals were found to carry a VUS. These individuals with 
a high relative probability of carrying a P/LP variant but no genetic diagnosis after 
panel testing are likely to be worth prioritising for future whole genome/exome 
sequencing studies.	
In summary, we found 4.9% of patients carried a P/LP variant as the underlying 
cause of their TAAD, predominantly within FBN1 but with substantial contributions 
from TGFBR and COL genes. Consistent with previous reports, amongst these cases 
were patients with non-syndromic TAAD in whom we found P/LP variants in genes 
normally associated with connective tissue disease. A higher likelihood of harbouring 
a P/LP variant was found to be associated with a syndromic component to the 
disease, early age at presentation, positive family history and aneurysm location in 
the ascending aorta. However, restricting genetic testing only to TAAD patients with 
these features is likely to miss a small but significant number of cases in whom a 
definitive genetic diagnosis could be made.	
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FIGURE LEGENDS	
Figure 1: Numbers of pathogenic or likely pathogenic (P/LP) variants identified by 
gene across both the Yale and UK cohorts. Percentages shown are the overall 
proportion of P/LP variants for each gene. 
Figure 2: Influence of variant type and diagnosis of Marfan syndrome on age of 
diagnosis. In cases with more than one P/LP variant or VUS, only the most damaging 
was included in this analysis. Age distribution and impact of age on variant type in 
whole cohort (a, b), and in non-Marfan patients (c, d).  
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Table	1	Patient	demographics	and	clinical	characteristics	of	the	cohort.		 	
		 Yale	Cohort	 UK	Cohort	
Whole	
Cohort	
Demographics	 	   
						Number	(%)	 732	(75.7)	 235	(24.3)	 967	(100)	
						Age	at	Diagnosis,	Median	 60	 60	 60	
														Min	 10	 11	 10	
														Max	 86	 84	 86	
						Male	(%)	a	 503	(68.7)	 154	(65.5)	 657	(67.9)	
						Female	(%)	 223	(30.4)	 80	(34.2)	 303	(31.3)	
						Caucasian	(%)	 634	(86.7)	 200	(85.2)	 833	(86.1)	
						Probable/Proven	Family	History	(%)	 214	(29.2)	 31	(13.2)	 245	(25.3)	
						No	Family	History	(%)	b	 444	(60.7)			 NA*	 NA*	
						Undergone	Aortic	Surgery	(%)		 732	(100)	 199	(84.7)	 931	(96.3)	
Primary	Aortic	Pathology		 	   
						Aneurysm	(%)	 650	(88.8)	 151	(64.3)	 801	(82.8)	
						Dissection	(%)	 72	(9.8)	 79	(33.6)	 151	(15.6)	
						PAU/IMH	(%)	 10	(1.4)	 4	(1.7)	 14	(1.4)	
						Rupture	(%)	 3	(0.4)	 2	(0.9)	 5	(0.5)	
Primary	Anatomical	Presentation		 	   
						Ascending/Arch	(%)	 683	(93.3)	 152	(64.7)	 835	(86.3)	
					Descending/Thoracoabdominal	(%)	 48	(6.6)	 83	(35.3)	 131	(13.5)	
Aortic	Size	 	   
						Maximum	Aortic	Diameter	(cm),	Median	 5.1	 5.5	 5.1	
												Min	 3.4	 2.7	 2.7	
												Max	 11	 13	 13	
						Maximum	Aortic	Diameter	<	5.5cm	(%)	 488	(66.7)	 103	(43.8)	 591	(61.1)	
Known	Syndrome	c	 	   
						MFS	(%)	 4	(0.5)	 20	(8.5)	 24	(2.5)	
						LDS	(%)	 0	(0)	 3	(1.3)	 3	(0.3)	
						EDS	(%)	 0	(0)	 0	(0)	 0	(0)	
					Other	(%)	d	 1	(0.1)	 2	(0.9)	 3	(0.3)	
PAU,	penetrating	aortic	ulcer.	IMH,	intramural	haematoma.	MFS,	Marfan	Syndrome.	LDS,	Loeys-Dietz	syndrome.	EDS,	Ehlers-
Danlos	syndrome.	NA,	not	available.	*	Absence	of	family	history	was	only	recorded	for	the	Yale	cohort.	a.	Gender	information	un	
available	for	7	patients.		b.	Family	history	unavailable	for	207	patients	in	UK	cohort	and	78	in	Yale	cohort.		c.	The	majority	of	
known	Marfan	patients	in	the	Yale	cohort	were	operated	on	as	emergencies	without	research	consent,	explaining	the	low	number	
of	Marfan	cases	within	the	Yale	cohort.	d.	One	individual	from	the	Yale	cohort	had	several	features	suggestive	of	a	connective	
tissue	disorder	but	did	not	fit	any	classic	syndrome	presentations	while	two	individuals	from	the	UK	cohort	had	scoliosis	in	
addition	to	TAAD.	
	
	
	
Table	2		Pathogenic	and	likely	pathogenic	variants	identified	by	the	NGS	panels	 	  
Gene	
Affected	 Variant	
Functional	
Category	 Classification	
Previously	
Reported?	 ID	
Primary	
Diagnosis	
Clinical	
Diagnosis	
Family	
History	
COL1A1	 c.1042G>A:p.A348T	 missense	 Likely	Pathogenic	 yes	 Y_109_21	 Aneurysm	 N/A	 no	
COL1A1	 c.1042G>A:p.A348T	 missense	 Likely	Pathogenic	 yes	 Y_17_1	 Dissection	 N/A	 no	
COL1A1	 c.2932C>T:p.Pro978Ser	 missense	 Likely	Pathogenic	 yes	 Y_12_61	 Aneurysm	 N/A	 no	
COL1A1	 c.2932C>T:p.Pro978Ser	 missense	 Likely	Pathogenic	 yes	 Y_50_38	 Aneurysm	 N/A	 yes	
COL3A1	 c.1178G>A:p.Gly393Asp	 missense	 Likely	Pathogenic	 no	 Y_5_23	 Aneurysm	 Other*	 yes	
COL3A1	 c.1204G>A:p.Gly402Ser	 missense	 Likely	Pathogenic	 no	 Y_112_51	 Aneurysm	 N/A	 no	
COL3A1	 c.1744G>A:p.Gly582Ser	 missense	 Pathogenic	 yes	 UK_24_0727	 Aneurysm	 N/A	 unknown	
COL3A1	 c.536delC:p.Pro179GlnfsTer43	 frameshift	 Pathogenic	 no	 Y_130_31	 Aneurysm	 N/A	 yes	
COL5A1	 c.2504G>C:p.Gly835Ala	 missense	 Likely	Pathogenic	 no	 Y_68_20	 Aneurysm	 N/A	 no	
COL5A2	 c.3275G>A:p.Gly1092Asp	 missense	 Likely	Pathogenic	 no	 UK_21_0261	 Aneurysm	 N/A	 unknown	
COL5A2	 c.808G>A:p.Gly270Ser	 missense	 Likely	Pathogenic	 no	 Y_1_1	 Aneurysm	 N/A	 yes	
FBN1	 c.59A>G:p.Tyr20Cys	 missense	 Likely	Pathogenic	 yes	 Y_128_61	 Aneurysm	 N/A	 no	
FBN1	 c.626G>A:p.Cys209Tyr	 missense	 Likely	Pathogenic	 yes	 Y_95_7	 Dissection	 N/A	 unknown	
FBN1	 c.1090C>T:p.Arg364Ter	 stop	gained	 Pathogenic	 yes	 UK_24_0907	 Aneurysm	 Marfan	 yes	
FBN1	 c.1090C>T:p.Arg364Ter	 stop	gained	 Pathogenic	 yes	 UK_24_0916	 Aneurysm	 Marfan	 yes	
FBN1	 c.1422T>G:p.Cys474Trp	 Missense	 Likely	Pathogenic	 yes	 UK_24_0712	 Dissection	 Marfan	 yes	
FBN1	 c.1468+5G>A	 splice	region	 Likely	Pathogenic	 yes	 UK_24_0719	 Aneurysm	 N/A	 unknown	
FBN1	 c.1468+5G>A	 splice	region	 Likely	Pathogenic	 yes	 UK_24_0720	 Aneurysm	 N/A	 unknown	
FBN1	 c.2168-1G>T	 splice	acceptor	 Likely	Pathogenic	 no	 Y_82_41	 Aneurysm	 N/A	 unknown	
FBN1	 c.2306G>A:p.Cys769Tyr	 missense	 Likely	Pathogenic	 yes	 UK_24_0904	 Aneurysm	 Marfan	 yes	
FBN1	 c.2554_2555dupAC:p.Cys853LeufsTer20	 frameshift	 Pathogenic	 no	 UK_21_0250	 Dissection	 Marfan	 yes	
FBN1	 c.2581C>T:p.Arg861Ter	 stop	gained	 Pathogenic	 yes	 Y_17_1	 Dissection	 N/A	 no	
FBN1	 c.2645C>T:p.Ala882Val	 missense	 Likely	Pathogenic	 yes	 UK_21_0003	 Aneurysm	 N/A	 unknown	
FBN1	 c.2896G>T:p.Glu966Ter	 stop	gained	 Pathogenic	 yes	 UK_21_0281	 Dissection	 N/A	 unknown	
FBN1	 c.3012C>G:p.Tyr1004Ter	 stop	gained	 Pathogenic	 yes	 UK_21_0083	 Dissection	 N/A	 unknown	
FBN1	 c.3193delG:p.Glu1065LysfsTer23	 frameshift	 Pathogenic	 yes	 Y_21_18	 Aneurysm	 N/A	 yes	
FBN1	 c.4406G>C:p.Arg1469Pro	 missense	 Likely	Pathogenic	 yes	 Y_133_86	 Aneurysm	 Marfan	 yes	
FBN1	 c.5235_5236dupTA:p.Thr1746IlefsTer148	 frameshift	 Pathogenic	 no	 UK_21_0242	 Aneurysm	 Marfan	 yes	
FBN1	 c.5917+6T>C	 splice	region	 Likely	Pathogenic	 yes	 UK_24_0796	 Aneurysm	 Marfan	 unknown	
FBN1	 c.5917+6T>C	 splice	region	 Likely	Pathogenic	 yes	 UK_24_0842	 Aneurysm	 Marfan	 yes	
FBN1	 c.6402dupC:p.Asp2135ArgfsTer4	 frameshift	 Pathogenic	 no	 UK_21_0355	 Aneurysm	 Marfan	 yes	
FBN1	 c.7039_7040delAT:p.Met2347ValfsTer19	 frameshift	 Pathogenic	 yes	 Y_26_51	 Aneurysm	 N/A	 no	
FBN1	 c.7788C>A:p.Tyr2596Ter	 stop	gained	 Likely	Pathogenic	 no	 Y_94_61	 Aneurysm	 N/A	 yes	
FBN1	 c.7956T>A:p.Cys2652Ter	 stop	gained	 Pathogenic	 no	 Y_47_31	 Aneurysm	 N/A	 yes	
FBN1	 c.8504dupC:p.Leu2836ThrfsTer3	 frameshift	 Likely	Pathogenic	 no	 Y_56_99	 Aneurysm	 N/A	 yes	
FBN1	 c.8504dupC:p.Leu2836ThrfsTer3	 frameshift	 Likely	Pathogenic	 no	 Y_59_47	 Aneurysm	 N/A	 yes	
MYH11	 c.1A>G:p.Met1?	 start	loss	 Likely	Pathogenic	 no	 Y_91_1	 Aneurysm	 N/A	 unknown	
MYH11	 c.4861A>C:p.Lys1621Gln	 missense	 Likely	Pathogenic	 yes	 Y_20_10	 Aneurysm	 N/A	 no	
MYH11	 c.5273G>A:p.Arg1758Gln	 missense	 Likely	Pathogenic	 yes	 Y_21_41	 Aneurysm	 N/A	 no	
MYH11	 c.5273G>A:p.Arg1758Gln	 missense	 Likely	Pathogenic	 yes	 Y_35_28	 Aneurysm	 Marfan	 no	
MYLK	 c.2390+2T>C	 splice	donor	 Likely	Pathogenic	 no	 Y_19_18	 Aneurysm	 N/A	 yes	
MYLK	 c.5275T>C:p.Ser1759Pro	 missense	 Likely	Pathogenic	 yes	 Y_84_18	 Dissection	 N/A	 yes	
SLC2A10	 c.394C>T:p.Arg132Trp	 missense	 Likely	Pathogenic	 yes	 Y_51_21	 Aneurysm	 N/A	 yes	
SLC2A10	 c.648C>G:p.Tyr216Ter	 stop	gained	 Pathogenic	 no	 Y_91_1	 Aneurysm	 N/A	 unknown	
TGFBR1	 c.974-2A>G	 splice	acceptor	 Likely	Pathogenic	 no	 Y_105_61	 Dissection	 N/A	 no	
TGFBR1	 c.1255+1G>A	 splice	donor	 Pathogenic	 no	 UK_21_1025	 Dissection	 N/A	 unknown	
TGFBR2	 c.1489C>T:p.Arg497Ter	 stop	gained	 Pathogenic	 yes	 Y_18_71	 Aneurysm	 N/A	 yes	
TGFBR2	 c.1524+1G>T	 splice	donor	 Pathogenic	 no	 UK_24_0795	 Aneurysm	 LDS	 unknown	
TGFBR2	 c.1609C>T:p.Arg537Cys	 missense	 Likely	Pathogenic	 no	 Y_112_30	 Aneurysm	 N/A	 yes	
LDS,	Loeys-Dietz	Syndrome.		
*This	individual	had	a	suspected	but	unconfirmed	connective	tissue	disorder 
  
	
Table	3	Probability	of	harbouring	a	pathogenic	or	likely	pathogenic	variant	according	to	phenotype	 	
		 Total	 Number	(Percentage)	with	a	Pathogenic	or	Likely	Pathogenic	Variant	Validated	by	Sanger	 RR	(95%	CI)	 P-Value	
Syndromic	 30	 13	(43)	 11.94	(7.06-20.20)	 9.89e-11	
Young	Age,	<	50	 237	 26	(11)	 3.83	(2.20-6.67)	 4.28e-6	
Known	or	Probable	Family	History	 257	 23	(9)	 3.80	(1.88-7.66)	 1.39e-4	
Ascending	Aorta	 477	 29	(6)	 1.84	(1.04-3.27)	 0.036	
Male	 694	 28	(4)	 0.68	(0.39-1.20)	 0.20	
Presence	of	Dissection	 158	 9	(6)	 1.28	(0.63-2.59)	 0.53	
Short-Term	Mortality*	 575	 24	(5)	 1.18	(0.42-3.32)	 1.00	
Large	Aortic	Diameter	(>5cm)	 612	 29	(5)	 1.05	(0.60-1.84)	 0.88	
*	Mortality	data	was	only	available	from	the	Yale	cohort	 		 		
	
